Search This Blog

Monday, December 30, 2013

Jim Chanos on CNBC talking about new short opportunities

Jim Chanos was recently on CNBC talking about the new opportunities he sees in the market for meaningful downside.  He thinks serial acquirers who aren't growing organically are a good target for shorting.  He wouldn't name names bud alluded that the biotech industry was particularly rife with this problem - makes me wonder if he is short Endo Health Solutions (ENDP) or Valeant Pharmaceuticals (VRX) which would be bold since that is a favorite among many hedge fund managers. Enjoy:

No comments: